Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.

Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.

An erythropoiet-derived peptide having an amino acid sequence as shown in SEQ ID NO: 1. A, method for preparing the above-described erythropoietin-derived peptide. Also provided is the rrse of the above-described erythropoietin-derived peptide fo the preparation of medicament for reatin$ nerve cell damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating hypoxic brain damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating epilepsy. The novel EPO-derived peptide of the present invention has a small molecular weight and can penetrate the blood-brain barrier. Moreover, it is a small-molecule polypeptide derived from a functional protein in the human body, having an extremely small side effect to the human body compared with other developed and synthesized thugs, thereby it has a good clinical application prospect.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.

The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.

Disclosed is a sensor for detecting the proximity of smart devices previously connected to the sensor using the IEEE 802.11 protocols. Importantly, the sensor does not operate using a Bluetooth® connection, which would require the smart devices previously connected to the sensor using the IEEE 802.11 protocols to also have Bluetooth® protocols enabled. Enabling such Bluetooth® protocols uses more battery than having the IEEE 802.11 protocol adapter enabled. The sensor references a list of previously connected smart devices and attempts to connect with any in range, if none can be connected to, the sensor emits an audible alarm signal. Further, no application is required for the sensor to operate.

Disclosed is a sensor for detecting the proximity of smart devices previously connected to the sensor using the IEEE 802.11 protocols. Importantly, the sensor does not operate using a Bluetooth® connection, which would require the smart devices previously connected to the sensor using the IEEE 802.11 protocols to also have Bluetooth® protocols enabled. Enabling such Bluetooth® protocols uses more battery than having the IEEE 802.11 protocol adapter enabled. The sensor references a list of previously connected smart devices and attempts to connect with any in range, if none can be connected to, the sensor emits an audible alarm signal. Further, no application is required for the sensor to operate.